Genetic polymorphisms of CYP2D6 in Chinese mainland

Chinese Medical Journal

Volumn 115, Issue 12, 2002, Pages 1780-1784

  Ji, Ling ^a   Pan, Shixiu ^a   Wu, Jianmin ^a   Marti Jaun, Jacqueline ^b   Hersberger, Martin ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Allele specific amplification PCR; Cytochrome P450 dependent monooxygenase; Metabolizer

Indexed keywords

CYTOCHROME P450 2D6;

ARTICLE; CAUCASIAN; CHINESE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; NORMAL HUMAN; POLYMERASE CHAIN REACTION; POPULATION GENETICS; RACE DIFFERENCE;

ALLELES; CHINA; CYTOCHROME P-450 CYP2D6; HUMANS; POLYMORPHISM, GENETIC;

EID: 0036960924     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Linder MW, Prough RA, Valdes RJ. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem 1997;43:254-266.
2. Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997;7:193-202.
3. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-295.
4. Alvan G, Bechtel P, Iselius L, et al. Hydroxylation polymorphisms of debrisoquine, and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-537.
5. Wanwimolruk S, Patamasucon P, Lee EJ. Evidence for the polymorphic oxidation of debrisoquine in the Thai population. Br J Clin Pharmacol 1990;29:244-247.
6. Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-397.
7. Lee EJ, Nam YP, Hee GN. Oxidation phenotyping in Chinese and Malay populations. Clin Exp, Pharmacol Physiol 1988;15:889-891.
8. Panserat S, Mura C, Gerard N, et al. DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers. Hum Genet 1994;94:401-406.
9. Wang SL, Lai MD, Huang JD. G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese. Drug Metab Dispos 1999;27:385-388.
10. Hersberger M, Marti-Jaun J, Rentsch K, et al. Rapid detection of the CYP2D6* 3, CYP2D6* 4, and GYP2D6* 6 alleles by tetra-primer PCR and of the CYP2D6* 5 allele by multiplex long PCR. Clin Chem 2000;46:1072-1077.
11. Garcia-Barcelo M, Chow LY, Chin HF, et al. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin Chem 2000;46:18-23.
12. Johansson I, Oscarson M, Yue QY, et al. Genetic analysis of the Chinese cytochrome, P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-459.
13. Bertilsson L, Aberg-Wistedt A, Gustafsson LL, et al. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline, and other tricyclic antidepressants. Ther Drug Monit 1985;7:478-480.
14. Kubota T, Yamaura Y, Ohkawa N, et al. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 2000;50:31-34.
15. Ryu Sw, Kim YJ, Kim E. Mutation analysis of CYP2D6 locus in Korean population: identification of rare poor metabolizer alleles at the nucleotide level. Mol Cells 1998;8:758-763.
16. Pang CP, Zhang J, Woo J, et al. Rarity of debrisoquine hydroxylase gene polymorphism in Chinese patients with Parkinson's disease. Mov Disord 1998;13:529-532.
17. Gan Y, Zhang Q. Polymorphisms of the GSTM1 and CYP2D6 genes associated with susceptibility to lung cancer in Chinese. Mutat Res 1999;444:441-449.
18. Lee EJ, Jeyaseelan K. Frequency of human CYP2D6 mutant alleles in a normal Chinese population. Br J Clin Pharmacol 1994;37:605-607.
19. Armstrong M, Fairbrother K, Idle JR, et al. The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics 1994;4:73-81.
20. Yokota H, Tamura S, Furuya H, et al. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 1993;3:256-263.
21. Yue QY, Zhong ZH, Tybring G, et al. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1998;64:384-390.
22. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999;20:342-349.